1. Home
  2. FMBH vs KALV Comparison

FMBH vs KALV Comparison

Compare FMBH & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Mid Bancshares Inc.

FMBH

First Mid Bancshares Inc.

HOLD

Current Price

$42.71

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$26.74

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FMBH
KALV
Founded
1865
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
FMBH
KALV
Price
$42.71
$26.74
Analyst Decision
Hold
Strong Buy
Analyst Count
5
5
Target Price
$43.40
$32.60
AVG Volume (30 Days)
65.2K
4.3M
Earning Date
04-29-2026
07-09-2026
Dividend Yield
2.33%
N/A
EPS Growth
16.06
N/A
EPS
1.06
N/A
Revenue
N/A
$50,000,000.00
Revenue This Year
$9.30
$185.42
Revenue Next Year
$6.66
$59.23
P/E Ratio
$40.40
N/A
Revenue Growth
N/A
495.66
52 Week Low
$33.67
$9.83
52 Week High
$44.85
$26.85

Technical Indicators

Market Signals
Indicator
FMBH
KALV
Relative Strength Index (RSI) 48.14 75.30
Support Level $42.36 $14.66
Resistance Level $42.85 N/A
Average True Range (ATR) 0.94 0.39
MACD -0.11 0.25
Stochastic Oscillator 48.18 98.72

Price Performance

Historical Comparison
FMBH
KALV

About FMBH First Mid Bancshares Inc.

First Mid Bancshares Inc is a United States based financial holding company. Through its wholly-owned subsidiary, First Mid Bank, it is engaged in the business of banking. The company offers trust, farm services, investment services, and retirement planning through its wholly owned subsidiary, it also provides data processing services to affiliates and insurance products and services to customers through its subsidiary. The company's operations cover community banking, wealth management and insurance services. Key revenue is derived from the provision of community banking services.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: